[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597870":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":24,"locations":30,"responsibleParty":46,"collaborators":18,"id":49,"slug":18,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":18,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":33,"whyStopped":18,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Shanghai Tongji Hospital, Tongji University School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Colchicine treatment group","EXPERIMENTAL","Adding low-dose colchicine on the basis of standardized treatment",[13],"Drug: Colchicine 0.5 MG Oral Tablet Once Daily",{"label":15,"type":16,"description":17,"interventionNames":18},"control group","NO_INTERVENTION","Standardized treatment",null,[20],{"type":21,"name":22,"description":22,"armGroupLabels":23,"otherNames":18},"DRUG","Colchicine 0.5 MG Oral Tablet Once Daily",[9],[25],{"name":26,"role":27,"phone":28,"phoneExt":18,"email":29},"Xuebo Liu","CONTACT","13801926702","lxb70@hotmail.com",[31],{"facility":32,"status":33,"city":34,"state":18,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Shanghai Tongji Hospital","RECRUITING","Shanghai","200000","China","CN",{"type":39,"coordinates":40},"Point",[41,42],121.45806,31.22222,{"lat":42,"lon":41},[45],{"name":26,"role":27,"phone":28,"phoneExt":18,"email":29},{"type":47,"investigatorFullName":26,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Director","100597870",false,"NCT07064109","Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in ACS Patients","Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in Acute Coronary Syndromes Patients","MCM-CATE-ACS","Inclusion Criteria:\n\n* Between the ages of 18 and 80\n* ACS (STEMI or NSTE-ACS)\n* Patients to receive standardised drug therapy\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Any contraindication to colchicine or known intolerance to colchicine\n* Has been using colchicine for a prolonged period of time for other medical conditions\n* Women of childbearing age who are pregnant, breastfeeding or not using effective contraception\n* Coronary artery bypass grafting within the last 3 years or planned\n* Severe hepatic impairment: elevated serum alanine aminotransferase and\u002For aminotransferase (ALT) and\u002For aminotransferase (AST) levels of up to three times the upper limit of normal\n* Severe renal impairment: eGFR \\\u003C30mL\u002Fmin\u002F1.73m2\n* Thrombocytopenia (platelet count less than 100\\*10⁹\u002FL)\n* Active diarrhoea\n* Infectious diseases: presence of uncontrollable infectious diseases\n* Immune-related diseases: known immune diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, malignant tumours, etc.\n* Strong CYP3A4 or P glycoprotein inhibitors (e.g., cyclosporine, antiretrovirals, antifungals, erythromycin and clarithromycin) are already in use and no alternative medications can be administered\n* Planning to use systemic anti-inflammatory therapies such as NSAIDs, hormones, immunomodulators and chemotherapeutic agents","ALL","18 Years","80 Years",{"count":60,"type":61},380,"ESTIMATED","INTERVENTIONAL",[64],"NA","The aim of this prospective cohort study was to investigate the multi-omics characteristics of the efficacy of colchicine treatment in patients with ACS and to construct a model of efficacy. The main questions the study aims to answer are\n\n\\- Specific mechanisms of colchicine therapy in patients with ACS; Mechanism-based modelling to identify the population that benefits from colchicine treatment.",[67],"ACS - Acute Coronary Syndrome",[69,70],"ACS","colchicine","2025-09-09",{"date":73,"type":74},"2025-09-15","ACTUAL",{"date":76,"type":74},"2025-07-01",{"date":78,"type":61},"2027-07-01",{"name":5,"class":6},1]